Compare AIT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIT | IBRX |
|---|---|---|
| Founded | 1923 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.4B |
| IPO Year | 1994 | 2015 |
| Metric | AIT | IBRX |
|---|---|---|
| Price | $286.01 | $7.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $302.00 | $12.57 |
| AVG Volume (30 Days) | 302.4K | ★ 22.1M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | 2.95 | ★ 38.71 |
| EPS | ★ 5.14 | N/A |
| Revenue | $21,485,000.00 | ★ $113,288,000.00 |
| Revenue This Year | $7.77 | $88.59 |
| Revenue Next Year | $5.41 | $131.15 |
| P/E Ratio | $55.74 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $212.00 | $1.83 |
| 52 Week High | $296.70 | $12.43 |
| Indicator | AIT | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 47.68 |
| Support Level | $254.61 | $2.25 |
| Resistance Level | $296.70 | $8.28 |
| Average True Range (ATR) | 7.90 | 0.82 |
| MACD | 3.39 | -0.08 |
| Stochastic Oscillator | 97.63 | 27.33 |
Applied Industrial Technologies Inc is a distributor of industrial products to the maintenance, repair, and operations market and the original equipment manufacturing industry. Further, the company provides engineering and design services for industrial and fluid power applications. The products include bearings, power transmission components, fluid power components and systems, industrial rubber products, linear motion components, safety products, oilfield supplies, and other industrial and maintenance supplies. The company's reportable segments are; Service Center Based Distribution which derives key revenue, and Engineered Solutions. Geographically, the company derives its key revenue from the United States and the rest from Canada and other countries.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.